Entering text into the input field will update the search result below

GSK boosts FY22 outlook while Q2 sales soar on Shingrix, Specialty drugs; sees impact on COVID products in H2

GlaxoSmithKline Headquarters In Brentford, London

Leon Neal

GSK (NYSE:GSK) Q2 sales grew on the back of growth in Specialty Medicines, including HIV, and shingles vaccine Shingrix, prompting the company to raise its FY22 sales outlook.

Q2 Non-GAAP EPS rose +23% Y/Y (at AER) to £0.347, while total sales grew +19% Y/Y to ~£6.93B.

Recommended For You

Related Stocks

SymbolLast Price% Chg
GSK
--
VIR
--